Iwamoto Hiroaki, Izumi Kouji, Nakagawa Ryunosuke, Toriumi Ren, Aoyama Shuhei, Kamijima Taiki, Shimada Takafumi, Kano Hiroshi, Makino Tomoyuki, Naito Renato, Kadomoto Suguru, Yaegashi Hiroshi, Kawaguchi Shohei, Nohara Takahiro, Shigehara Kazuyoshi, Kadono Yoshifumi, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa 920-8641, Japan.
Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa 920-8530, Japan.
Biomedicines. 2022 Sep 22;10(10):2369. doi: 10.3390/biomedicines10102369.
Purpose: Prostate-specific antigen (PSA) is a useful prostate cancer (PC) biomarker, but some cases reported that PSA does not correlate with the Gleason score. Serum chemokine (CC motif) ligand 2 (CCL2) has been reported to be a potential complementary PSA biomarker, but it remains unclear whether it can be applied to non-metastatic castration-sensitive prostate cancer (nmCSPC) or each section of the stages. Serum CCL2′s usefulness was investigated as a prognostic nmCSPC biomarker in this study. Methods: Serum samples were collected from 379 patients who underwent prostate biopsy at Kanazawa University Hospital from 2007 to 2013. A total of 230 patients with nmCSPC were included in this study of the 255 patients with histologically diagnosed prostate cancer. The serum CCL2 efficacy as a prognostic nmCSPC biomarker was investigated retrospectively. Results: An independent significant predictor of worse OS was CCL2 ≥ 280 pg/dL and CRP ≥ 0.5 mg/dL in multivariate analysis. Gleason score ≥ 8 and CCL2 ≥ 280 pg/dL were independent significant predictors of CRPC-free survival (CFS) worsening in multivariate analysis. Serum CCL2 was a predictive biomarker for OS and CFS in nmCSPC. Furthermore, CCL2 ≥ 280 pg/mL patients had significantly worse visceral metastasis-free survival than those with CCL2 < 280 pg/mL. Conclusion: This study is the first to demonstrate serum CCL2 utility as a biomarker to predict OS and CFS in nmCSPC.
前列腺特异性抗原（PSA）是一种有用的前列腺癌（PC）生物标志物，但一些病例报告显示PSA与Gleason评分不相关。血清趋化因子（CC基序）配体2（CCL2）已被报道为一种潜在的补充PSA生物标志物，但尚不清楚它是否可应用于非转移性去势敏感性前列腺癌（nmCSPC）或各分期。本研究调查了血清CCL2作为nmCSPC预后生物标志物的效用。方法：收集2007年至2013年在金泽大学医院接受前列腺活检的379例患者的血清样本。在255例经组织学诊断为前列腺癌的患者中，共有230例nmCSPC患者纳入本研究。回顾性研究血清CCL2作为nmCSPC预后生物标志物的疗效。结果：多因素分析显示，CCL2≥280 pg/dL和CRP≥0.5 mg/dL是总生存期较差的独立显著预测因素。多因素分析显示，Gleason评分≥8和CCL2≥280 pg/dL是无去势抵抗性前列腺癌生存期（CFS）恶化的独立显著预测因素。血清CCL2是nmCSPC总生存期和CFS的预测生物标志物。此外，CCL2≥280 pg/mL的患者无内脏转移生存期明显低于CCL2<280 pg/mL的患者。结论：本研究首次证明血清CCL2作为预测nmCSPC总生存期和CFS的生物标志物的效用。
